Somerville Kurt F Makes New Investment in AbbVie Inc. $ABBV

Somerville Kurt F purchased a new stake in AbbVie Inc. (NYSE:ABBV – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 5,261 shares of the company’s stock, valued at approximately $1,324,000.

Several other institutional investors have also recently made changes to their positions in the company. MSH Capital Advisors LLC acquired a new position in AbbVie in the second quarter valued at approximately $4,483,000. Puzo Michael J acquired a new position in shares of AbbVie in the 2nd quarter valued at $2,206,000. Quartz Partners LLC purchased a new position in shares of AbbVie during the 2nd quarter worth $2,040,000. Frazier Financial Advisors LLC purchased a new position in shares of AbbVie during the 2nd quarter worth $4,171,000. Finally, Northcape Wealth Management LLC acquired a new stake in shares of AbbVie during the 2nd quarter worth about $3,047,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Get AbbVie alerts:

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Skyrizi regulatory expansion: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of Skyrizi in adults with moderately to severely active Crohn’s disease. If approved, the less invasive option could improve patient convenience, strengthen Skyrizi’s European franchise and support longer-term immunology revenue. The filing is backed by positive Phase 3 AFFIRM data. AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn’s Disease
• Positive Sentiment: Additional IBD pipeline investment: AbbVie is conducting a Phase 2 platform basket trial evaluating potential treatments across Crohn’s disease and ulcerative colitis. The study adds longer-term pipeline optionality and may help diversify growth beyond existing immunology products, although it remains an early-stage catalyst. AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial
• Neutral Sentiment: Income-oriented appeal: Recent market commentary highlights AbbVie among established dividend stocks, reinforcing its defensive profile and appeal to income investors. This is supportive of sentiment but does not represent a new company-specific announcement. 3 Dividend Stocks, 12 Paychecks a Year
• Negative Sentiment: Valuation risk: With ABBV trading at a high earnings multiple and close to its 52-week peak, investors may be concerned that substantial future growth is already reflected in the share price. Any regulatory delay or disappointing pipeline data could therefore produce an outsized reaction. Has AbbVie Stock Become Too Expensive to Buy?

Analyst Ratings Changes

Several research analysts have weighed in on ABBV shares. Barclays increased their target price on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Morgan Stanley reiterated an “overweight” rating and issued a $296.00 target price on shares of AbbVie in a report on Monday, August 3rd. Evercore set a $235.00 price target on AbbVie in a research note on Friday, May 15th. JPMorgan Chase & Co. raised their price target on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Finally, Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $275.95.

Get Our Latest Research Report on AbbVie

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.06% of the company’s stock.

AbbVie Trading Up 0.2%

NYSE:ABBV opened at $256.08 on Monday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47. The firm has a market cap of $452.44 billion, a PE ratio of 72.34, a price-to-earnings-growth ratio of 0.85 and a beta of 0.30. The stock has a fifty day moving average price of $252.66 and a 200 day moving average price of $228.91.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts forecast that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s payout ratio is 195.48%.

AbbVie Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.

Read More

• Five stocks we like better than AbbVie
• Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
• Rubrik’s AI Security Bet Could Power the Next Leg Higher
• Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
• Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.